Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Foghorn Therapeutics Inc.
|
|
| Balance Sheet |
|
|
|
| Standardized | As Reported |
Annual | Quarterly |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Assets |
| Cash and equivalents | 57.7 | 50.6 | 52.2 | 87.6 | 61.2 | 213.6 | 101.1 | 57.8 |
| Short-term investments | 226.6 | 265.3 | 293.6 | 285.9 | 333.5 | 211.1 | 53.2 | 63.0 |
| Other current assets | 6.2 | 4.7 | 5.6 | 4.3 | 5.3 | 5.1 | 305.3 | 3.1 |
| Total current assets | 290.5 | 320.7 | 351.4 | 377.8 | 400.1 | 429.8 | 459.6 | 124.0 |
| Other fixed assets | 1.2 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 |
| Total assets | 339.6 | 372.9 | 404.9 | 433.9 | 456.9 | 488.3 | 519.8 | 186.1 |
| |
| Accounts payable | 6.9 | 7.3 | 5.4 | 5.3 | 3.6 | 5.1 | 3.8 | 3.8 |
| Accrued expenses | 4.1 | 2.2 | 5.4 | 5.0 | 3.6 | 2.1 | 6.1 | 7.2 |
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other current liabilities | 45.6 | 46.3 | 44.4 | 44.9 | 40.7 | 41.1 | 38.8 | 8.3 |
| Total current liabilities | 56.6 | 55.8 | 55.2 | 55.2 | 48.0 | 48.2 | 48.7 | 19.3 |
| Long-term debt | | | | | | | | 19.9 |
| Other liabilities | 332.3 | 341.7 | 349.6 | 354.4 | 361.3 | 367.7 | 374.2 | 65.9 |
| Total liabilities | 388.9 | 397.5 | 404.8 | 409.6 | 409.3 | 415.9 | 422.9 | 105.1 |
| |
| Shareholders' equity [+] | -49.4 | -24.6 | 0.1 | 24.3 | 47.6 | 72.4 | 96.9 | 81.0 |
| Paid-in capital | 386.5 | 381.9 | 377.2 | 373.4 | 369.3 | 364.8 | 361.1 | 316.1 |
| Retained earnings | -433.1 | -403.6 | -373.1 | -344.3 | -318.5 | -291.2 | -264.3 | -235.1 |
| Tangible shareholders' equity | -49.4 | -24.6 | 0.1 | 24.3 | 47.6 | 72.4 | 96.9 | 81.0 |
|